ADC Development Pipeline
By using all of the validated and proprietary technology platforms developed at NBE-Therapeutics, we have started to create an early preclinically validated portfolio of ADC product candidates.
In addition to ADCs against established and validated cancer targets, which are either out-licensed already (CD19 and HER-2) or potentially available for out-licensing (CD30), NBE-Therapeutics scientists have developed a preclinically validated portfolio of ADCs in four different cancer target programs, which address a wide variety of hematologic malignancies or solid tumors. Two lead programs are currently undergoing final lead optimization and characterization, and are expected to enter into IND-enabling development and cGMP manufacturing during Q1-2017. The current pipeline and status of NBE-Therapeutics' ADC development candidates is displayed below.
- Basel, 2018-11-15 - Dr. Anthony Tolcher joins the Scientific Advisory Board of NBE-Therapeutics
- Basel, 2018-10-29 - NBE-Therapeutics was invited to present at Terrapinn's 2018 European Antibody Congress
- Basel, 2018-06-28 - Novo Holdings A/S invests CHF 20 million in a seriesB extension financing of NBE-Therapeutics